EMA Head On Transparency, Affordable Innovation, And What Patients Really Need
This article was originally published in SRA
Guido Rasi, the newly re-appointed executive director of the European Medicines Agency, has outlined his priorities for the next five years1. Among them are steering R&D towards new treatments with real potential to fulfil unmet medical needs, streamlining the regulatory system to give companies an incentive to keep down drug prices, and involving patients even more closely in the EMA's work.
Register for our free email digests: